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OBJECTIVE: The objective of this study was to determine the
health economic impact of paricalcitol versus standard non-
selective vitamin D receptor activators (VDRA) treatment for
secondary hyperparathyroidism in patients with chronic kidney
disease (CKD) in the US. METHODS: A Markov process model
was developed employing data sources from the published litera-
ture, paricalcitol clinical trials, and national population statistics.
The comparator was calcitriol, a non-selective VDRA medica-
tion. The primary perspective of the study was that of the third
party payor. The outcomes in the paricalcitol clinical trials and
observational studies (reduction SHPT, reduction proteinuria,
complications and mortality) were extrapolated to number of life
years gained (LYG) and number of quality-adjusted life-years
(QALYs). Clinical and economic outcomes were discounted at
3.5%. RESULTS: The base case analysis is based on a 10-years
time horizon and is based on a comparison of paricalcitol with a
non-selective VDRA, which is started in CKD 3 and continued in
CKD 4 and CKD 5. The use of paricalcitol leads to a reduction
in medical cost of $2528 and an increase in LYG (0.47 years) and
a gain in QALYs (0.43). Consequently the use of paricalcitol
result is a dominant strategy, costing less and more effective,
from the primary perspective of the US third party payor. The
incremental cost-effectiveness ratio remained dominant from the
perspective of the society after inclusion of indirect costs. One-
way sensitivity analyses and probabilistic sensitivity analyses
conﬁrmed the robustness of the model. CONCLUSION: The
results showed that the favorable clinical beneﬁt of paricalcitol
results in positive health economic beneﬁts in CKD Stages 3, 4, &
5. This study suggests that the use of paricalcitol in patients
with early CKD may be cost-effective from a third party payor
perspective when compared to standard non-selective VDRA
medication.
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OBJECTIVE: Renal transplantation is recognized as the pre-
ferred approach to the management of end-stage renal disease,
from both the clinical and economic perspective. In Mexico,
approximately 20% of patients show acute rejection in renal
transplantation (ARRT) during the ﬁrst year. The purpose of
this study was to estimate the cost-effectiveness of three differ-
ent antibodies for the management of patients with ARRT at
the Social Security Mexican Institute (IMSS). METHODS: A
one-year decision tree model was performed to simulate costs
and health outcomes from an institutional perspective. Effec-
tiveness measure was the rate of survival graft’s rescued at
the end of the follow-up period. Efﬁcacy data and transition
probabilities were taken from published literature. Compara-
tors were horse anti-human thymocyte globulin (10mg/kg);
rabbit anti-human thymocyte globulin ATG(1.5mg/kg) and
Mono-OKT3(5mg). Resource use was obtained from local
experts and direct costs were calculated through case-mix
methodology (all unit costs were taken from ofﬁcial databases).
The model was calibrated according to international pharma-
coeconomics guidelines. One-way and probabilistic sensitivity
analyses were performed using Monte Carlo Simulation second-
order approach. RESULTS: The higher effectiveness was
obtained by horse-ATG (87.93%) followed by the rabbit-ATG
(84.13%) and OKT3 therapy (82.13%). OKT3 therapy showed
the lowest costs per patient (US$91,719) followed by horse-
ATG (US$95,875) and rabbit-ATG (US$97,400). The horse-
ATG showed the lowest cost per case rescued. ICERs showed
that rabbit-ATG is dominated by horse-ATG and OKT3 and
the horse-ATG obtained an ICER of US$75,994 vs. OKT3
(baseline). One-way analyses showed that variation in price and
effects don’t change these results (p < 0.05). Probabilistic sen-
sitivity analyses employing acceptability curves and component
analyses showed that the horse-ATG therapy was the most
cost-effective treatment. CONCLUSION: In Mexico, horse-
ATG demonstrated to be a cost-effective polyclonal antibody
for high risk patients with ARRT. These results should be taken
into account by Mexican decision makers in future cost-
containment policies.
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OBJECTIVE: To assess the direct medical cost of three therapeu-
tic alternatives for ureteral calculi using a decision tree model
from the payer perspective. METHODS: Taiwan National
Health Insurance (NHI) claim databases were used to identify
new ureteral stones subjects who initially underwent three treat-
ment modalities: observation, ureteroscopy (URS), and shock
wave lithotripsy (SWL) between January 1, 2004-September 30,
2006. A subject identiﬁcation period spanned from July 1, 2004-
June 30, 2006. URS subjects were matched to SWL subjects on
the propensity score to avoid possible selection bias. The single
treatment cost per patient of each of strategies was obtained from
the cumulative sum of various pay procedures according to NHI
reimbursement fee schedules. The decision tree model was used
to compute the expected total treatment costs per patient. Sen-
sitivity analysis was done to evaluate the effects of various
success rates and costs. RESULTS: Of 13,594 eligible subjects,
there were 3426 (25.2%) with observation, 2738 (20.1%) with
URS and 7430 (54.7%) with SWL. A total of 1467 subject pairs
were obtained after propensity score matching. Observation was
the least costly pathway at all ureteral sites when observation
failed. URS was less costly than SWL for stones at mid and distal
ureteral locations and a cost difference of T$3535 and T$3072
was noted between the two modalities. Likewise, URS was more
costly than SWL for proximal stones by T$2321. One-way sen-
sitivity analysis showed the cost of URS could be increased by
more than T$4166 and T$3559, and the success rate could be
decreased by 11% and 10% for middle and distal stones before
attaining cost equivalence with SWL. CONCLUSION: URS was
less costly than SWL for treatment of middle and distal ureteral
stones. However, the cost of URS would exceed the cost of SWL
for the treatment of proximal stones. Observation was the least
costly pathway.
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